Filtered By:
Condition: Thrombosis
Nutrition: Vitamin A

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Serum levels of antibodies against oxidation-specific epitopes are decreased in patients with retinal vein occlusion
Conclusion: These prospective data show that antibodies against oxidation-specific epitope are lower in patients with RVO compared with control patients and support the concept that oxidative stress and inflammation play key roles in the development and subsequent complications in RVO.
Source: RETINA - May 27, 2021 Category: Opthalmology Tags: Original Study Source Type: research

Tissue-Based Stroke Definition Impacts Stroke Incidence but not Ethnic Differences
In 2013, a new stroke definition was promulgated.1 Ischemic stroke was defined as an episode of neurologic dysfunction resulting from “CNS infarction.” The term CNS infarction included not only patients with clinical symptoms lasting greater than 24 h, but also those who had MRI diffusion positive signal with symptoms less than 24 h in duration. It also included retinal and spinal cord infarction as well as cerebral venous s inus thrombosis with infarction. All of these factors would increase previous estimates of ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 21, 2021 Category: Neurology Authors: Lewis B. Morgenstern, Darin B. Zahuranec, Jaewon Lim, Xu Shi, Devin L. Brown, Kevin A. Kerber, William J. Meurer, Lesli E. Skolarus, Eric E. Adelman, Morgan S. Campbell, Erin Case, Lynda D. Lisabeth Source Type: research

Comments on Coronavirus Positive Patients Presenting with Stroke-Like Symptoms
We read with interest the short communication entitled “Coronavirus Positive Patients Presenting with Stroke-Like Symptoms”,1 it was a case series on stroke presentation over COVID-19 patients. We are particularly interested on patient 10, the one and only one central retinal artery occlusion (CRAO) case secondary to occlusive thrombus in the intern al carotid artery (ICA), who was also highlighted by the authors. CRAO is a blinding ocular emergency, and a harbinger of ischemic cerebrovascular stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 10, 2021 Category: Neurology Authors: Sunny Chi Lik Au, Callie Ka Li Ko Tags: Letter to Editor Source Type: research

Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer
CONCLUSION: In this observational study of an aggregated US patient population, those with newly diagnosed cancer had increased risk of ATE events. This risk was most elevated in a 330-day window around cancer diagnosis and was consistent across different types of ATE and cancer.PMID:33673912 | DOI:10.1016/j.mayocp.2020.05.045
Source: Clinical Colorectal Cancer - March 6, 2021 Category: Cancer & Oncology Authors: Jiasheng Wang Yeseong D Kim Chang H Kim Source Type: research

Aneurysms in primary antiphospholipid syndrome: a case-based review
This article review ed all published cases on APS and aneurysm and showed that women who presented with abortions and deep venous thromboses with a lupus anticoagulant are those patients more commonly affected by aneurysms in APS.
Source: Clinical Rheumatology - January 3, 2021 Category: Rheumatology Source Type: research

Intravenous Recombinant Tissue-Type Plasminogen Activator Thrombolysis for Acute Central Retinal Artery Occlusion
Discussion: This meta-analysis indicated that intravenous rt-PA thrombolysis could be an effective and safe strategy for the management of CRAO. However, a more detailed large-scale clinical trial is warranted to strengthen the evidence-based therapeutic guidance.
Source: Journal of Craniofacial Surgery - January 1, 2021 Category: Surgery Tags: Clinical Studies Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news